Price T Rowe Associates Inc. MD Buys New Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Price T Rowe Associates Inc. MD bought a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,715 shares of the company’s stock, valued at approximately $145,000.

Several other hedge funds have also recently added to or reduced their stakes in MLYS. China Universal Asset Management Co. Ltd. boosted its stake in Mineralys Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after purchasing an additional 989 shares during the period. EntryPoint Capital LLC bought a new stake in Mineralys Therapeutics during the 4th quarter valued at approximately $154,000. AlphaQuest LLC boosted its stake in Mineralys Therapeutics by 2,637.8% during the 4th quarter. AlphaQuest LLC now owns 15,222 shares of the company’s stock valued at $187,000 after purchasing an additional 14,666 shares during the period. Dimensional Fund Advisors LP bought a new stake in Mineralys Therapeutics during the 4th quarter valued at approximately $202,000. Finally, SG Americas Securities LLC boosted its stake in Mineralys Therapeutics by 119.0% during the 4th quarter. SG Americas Securities LLC now owns 19,961 shares of the company’s stock valued at $246,000 after purchasing an additional 10,845 shares during the period. Institutional investors own 84.46% of the company’s stock.

Insiders Place Their Bets

In other news, insider David Malcom Rodman sold 11,366 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $15.29, for a total value of $173,786.14. Following the completion of the transaction, the insider now directly owns 106,669 shares of the company’s stock, valued at approximately $1,630,969.01. This represents a 9.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the transaction, the chief financial officer now directly owns 215,340 shares of the company’s stock, valued at approximately $2,597,000.40. The trade was a 4.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 104,579 shares of company stock worth $1,534,353. 25.56% of the stock is currently owned by company insiders.

Mineralys Therapeutics Trading Down 0.1%

Shares of MLYS stock opened at $15.35 on Friday. The stock has a 50 day moving average of $14.29 and a two-hundred day moving average of $12.47. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $18.38. The company has a market capitalization of $995.85 million, a P/E ratio of -4.22 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.23. Sell-side analysts predict that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. The Goldman Sachs Group decreased their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $42.00 price objective on shares of Mineralys Therapeutics in a research report on Tuesday, May 13th.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.